Satheesh Chiradoni Thungappa
@drsatheeshct
MD,DM, ESMO, FRCP(Edin),MBA, Prof of Medical Oncology and Director of Clinical Trials, HCG Enterprises Ltd.
ID: 2149537178
22-10-2013 18:46:26
104 Tweet
174 Followers
1,1K Following
#Germline alteration risk in #bladdercancer: 10-15% in unselected patients; 20-25% in selected high-risk patient with young age, other suspicious cancers in patient & family history of cancers suspicious for familial cancer @practiceupdate OncoAlert Bladder Cancer Advocacy Network Dr. Bishoy M. Faltas
Agree! Unfortunately, there are still a large number of patients receiving ADT monotherapy. It is very important to adapt results of clinical trials in to daily clinical practice and make accessible to our patients. OncoAlert Advanced Prostate Cancer Consensus Conference PCF Science ESMO - Eur. Oncology ASCO European Association of Urology (EAU)
Excited to be in Paris today - pass by the poster area for a quick chat about BRAF mutations ESMO - Eur. Oncology
Rebecca Shatsky, MD Santhosh Ambika Hope Rugo Paolo Tarantino OncoAlert Agree Rebecca Shatsky, MD - saci is better than chemo and I have no reservations using. Based also on line where tested I feel more confident with TDXd 1st and saci after. But let's be honest, patients will need both!
Just in Clinical Cancer Research: Happy to report👉SPOP mutation as 1st treatment selection biomarker in mCSPC #ProstateCancer , predicts response to ARAT & not to docetaxel bit.ly/3U1d88k Neeraj Agarwal, MD, FASCO Emmanuel Antonarakis @RyonGraff Geoff Oxnard MD OncoAlert PCF Science Tweetorial (1/10)